Endocrine Abstracts

Prior to therapy, patients choosing I131 therapy for the treatment of Grave’s disease were pre treated with carbimazole. Post I131 they have their thyroid function checked monthly in primary care prior to clinic review at 3 months. Carbimazole can be restarted if clinically indicated and treatment with thyroxine was recommended if their TSH was greater than 3.5 mU/l (ref range 0.35–5.5). A previous audit had demonstrated that 24% of patients had an elevated TSH great...

Background: Transient hypocalcaemia post parathyroid or thyroidectomy is common. Locally, post operative follow up was Ad-hoc with weekly visits where one of the Endocrine team would reduce Adcal D3© or 1α-Hydroxycholecalciferol doses to maintain eucalcaemia. This was frustrating for staff and patients who spent weeks and sometimes months having weekly blood tests. In an effort to improve the experience we piloted a pathway based on fixed dose replacement and day 1 p...

Background: Radioactive iodine (RAI) is a safe and effective treatment for management of hyperthyroidism caused by Graves’ disease and multinodular goitres. However, patient engagement with this therapy is limited by concerns regarding significant weight gain following treatment. We therefore aimed to audit weight changes in individuals receiving RAI within our service and identify factors that may influence this outcome.Met...

Background: Functioning gonadotroph adenomas (FGA) are rare benign pituitary tumours. Several case reports suggest that FGA may present with features of ovarian hyperstimulation in women. However, a lack of aggregated clinical experience of FGA precludes the meaningful guidance of management in affected women.Methods: Case series of 7 women presenting at different UK sites with FGA induced ovarian hyperstimulation syndrome (OHSS).R...